ClinicalTrials.gov record
Recruiting Phase 2Phase 3 Interventional

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

ClinicalTrials.gov ID: NCT06236438

Public ClinicalTrials.gov record NCT06236438. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 3:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Study identification

NCT ID
NCT06236438
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
AbbVie
Industry
Enrollment
840 participants

Conditions and interventions

Interventions

  • Budigalimab Drug
  • Carboplatin Drug
  • Cisplatin Drug
  • Livmoniplimab Drug
  • Pembrolizumab Drug
  • Pemetrexed Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 9, 2024
Primary completion
Sep 30, 2031
Completion
Sep 30, 2031
Last update posted
Feb 22, 2026

2024 – 2031

United States locations

U.S. sites
19
U.S. states
14
U.S. cities
19
Facility City State ZIP Site status
Moores Cancer Center /ID# 267782 La Jolla California 92037 Recruiting
Memorial Hospital West /ID# 262221 Pembroke Pines Florida 33028 Recruiting
Bond Clinic /ID# 262611 Winter Haven Florida 33880 Recruiting
University Cancer & Blood Cent /ID# 261824 Athens Georgia 30607 Recruiting
The University of Chicago Medical Center /ID# 262259 Chicago Illinois 60637-1443 Recruiting
University of Kansas Medical Center /ID# 263196 Westwood Kansas 66205 Recruiting
Baptist Health Lexington /ID# 261823 Lexington Kentucky 40503 Recruiting
Cancer & Hematology Centers of Western Michigan - East /ID# 261826 Grand Rapids Michigan 49546-7062 Recruiting
Washington University-School of Medicine /ID# 262759 St Louis Missouri 63110 Recruiting
Stony Brook Cancer Center /ID# 261954 Stony Brook New York 11794-0001 Recruiting
Cone Health Cancer Center /ID# 262583 Greensboro North Carolina 27403-1109 Recruiting
Oncology Hematology Care, Inc - Blue Ash /ID# 262733 Cincinnati Ohio 45252 Recruiting
Guthrie Robert Packer Hospital /ID# 262758 Sayre Pennsylvania 18840 Recruiting
Renovatio clinical /ID# 262000 El Paso Texas 79915-1803 Completed
Houston Methodist Hospital /ID# 262722 Houston Texas 77030 Recruiting
Texas Oncology - Plano East /ID# 264356 Plano Texas 75075 Recruiting
Texas Oncology - San Antonio Medical Center - Research Drive /ID# 264311 San Antonio Texas 78240 Recruiting
Renovatio Clinical /ID# 261999 The Woodlands Texas 77380-3181 Completed
Vista Oncology - East Olympia /ID# 262303 Olympia Washington 98506-5028 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06236438, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 22, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06236438 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →